FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.

被引：0
|
作者：
Li, Qiao
Cheng, Ying
Tong, Zhongsheng
Liu, Yunjiang
Wang, Xian
Yan, Min
Chang, Jianhua
Wang, Shusen
Du, Caiwen
Li, Liang
Wu, Chunjiao
Wang, Mingxia
Wang, Zhuo
Wu, Zhuli
Jin, Yongli
Zhang, Yongjiao
Hui, Ai-Min
Wang, Xingli
Xu, Binghe
机构：
[1] Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Tianjin, Peoples R China
[4] Hebei Med Univ, Dept Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[6] Zhengzhou Univ, Dept Breast Dis, Henan Breast Canc Ctr, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[7] Henan Canc Hosp, Zhengzhou, Peoples R China
[8] Chinese Acad Med Sci, Shenzhen Ctr, Dept Med Oncol, Canc Hosp, Shenzhen, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[10] Meizhou Peoples Hosp, Dept Med Oncol, Meizhou, Guangdong, Peoples R China
[11] Jilin Canc Hosp, Dept Oncol, Phase ward 1, Changchun, Jilin, Peoples R China
[12] Hebei Med Univ, Dept Phase 1, Clin Trial Unit, Hosp 4, Shijiahuang, Hebei, Peoples R China
[13] Beijing Fosun Pharmaceut Res & Dev Co Ltd, Shanghai, Peoples R China
[14] Fosun Pharma USA Inc, Lexington, MA USA
[15] Shanghai Fosun Pharmaceut Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3044
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study
    Hong, Ruoxi
    Xia, Wen
    Wang, Liye
    Lee, Kaping
    Lu, Qianyi
    Jiang, Kuikui
    Li, Shengfeng
    Yu, Jinquan
    Wei, Jin
    Tang, Weijia
    Zhou, Danyang
    An, Xin
    Huang, Jiajia
    Xue, Cong
    Bi, Xiwen
    Shi, Yanxia
    Yuan, Zhongyu
    Xu, Fei
    Wang, Shusen
    CANCER COMMUNICATIONS, 2021, 41 (02) : 171 - 182
  • [32] An open-label, multicentre, phase IIIb study with intravenous administration of pertuzumab, subcutaneous trastuzumab, and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)
    Woodward, Natasha
    De Boer, Richard H.
    Redfern, Andrew
    Von Neumann-Cosel, Vita
    Heath, Ronelle M.
    Beith, Jane
    CANCER RESEARCH, 2015, 75
  • [33] Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial
    Cao, F.
    Ma, Z.
    Hu, G.
    Zhu, X.
    Li, S.
    Chen, S.
    Chen, B.
    Li, Z.
    Wu, W.
    Ji, X.
    Shu, J.
    Tao, D.
    Hu, X.
    Zheng, M.
    Wang, O.
    Feng, Q.
    Hao, J.
    Li, X.
    BREAST, 2023, 68 : S16 - S16
  • [34] Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study
    Jackisch, C.
    Stroyakovskiy, D.
    Muehlbauer, S.
    Heinzmann, D.
    Kopp, M. V.
    Ahn, J. S.
    Staroslawska, E.
    Falcon, S.
    Pivot, X.
    Ismael, G.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S37 - S37
  • [35] Updated safety results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)
    Woodward, N.
    De Boer, R. H.
    Redfern, A.
    White, M.
    Roberts, W.
    Truman, M.
    Beith, J.
    CANCER RESEARCH, 2017, 77
  • [36] Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
    Goel, Shom
    Pernas, Sonia
    Tan-Wasielewski, Zhenying
    Barry, William T.
    Bardia, Aditya
    Rees, Rebecca
    Andrews, Chelsea
    Tahara, Rie Kawabori
    Trippa, Lorenzo
    Mayer, Erica L.
    Winer, Eric P.
    Spring, Laura M.
    Tolaney, Sara M.
    CLINICAL BREAST CANCER, 2019, 19 (06) : 399 - 404
  • [37] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
    Hurvitz, Sara A.
    Hegg, Roberto
    Chung, Wei-Pang
    Im, Seock-Ah
    Jacot, William
    Ganju, Vinod
    Chiu, Joanne Wing Yan
    Xu, Binghe
    Hamilton, Erika
    Madhusudan, Srinivasan
    Iwata, Hiroji
    Altintas, Sevilay
    Henning, Jan-Willem
    Curigliano, Giuseppe
    Perez-Garcia, Jose Manuel
    Kim, Sung-Bae
    Petry, Vanessa
    Huang, Chiun-Sheng
    Li, Wei
    Frenel, Jean-Sebastien
    Antolin, Silvia
    Yeo, Winnie
    Bianchini, Giampaolo
    Loi, Sherene
    Tsurutani, Junji
    Egorov, Anton
    Liu, Yali
    Cathcart, Jillian
    Ashfaque, Shahid
    Cortes, Javier
    LANCET, 2023, 401 (10371): : 105 - 117
  • [38] Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
    Pierga, Jean-Yves
    Petit, Thierry
    Delozier, Thierry
    Ferrero, Jean-Marc
    Campone, Mario
    Gligorov, Joseph
    Lerebours, Florence
    Roche, Henri
    Bachelot, Thomas
    Charafe-Jauffret, Emmanuelle
    Pavlyuk, Maria
    Kraemer, Sandrine
    Bidard, Francois-Clement
    Viens, Patrice
    LANCET ONCOLOGY, 2012, 13 (04): : 375 - 384
  • [39] A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
    Johnston, Stephen R. D.
    Gomez, Henry
    Stemmer, Salomon M.
    Richie, Maria
    Durante, Michael
    Pandite, Lini
    Goodman, Vicki
    Slamon, Dennis
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (03) : 755 - 766
  • [40] A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
    Stephen R. D. Johnston
    Henry Gómez
    Salomon M. Stemmer
    Maria Richie
    Michael Durante
    Lini Pandite
    Vicki Goodman
    Dennis Slamon
    Breast Cancer Research and Treatment, 2013, 137 : 755 - 766
12345